Monitor upcoming Q1 2026 earnings for confirmation of the $744 million IPR&D expense and final EPS results; the updated guidance range implies slightly lower profitability expectations for the year.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $204.99entry
- T+1 · 7mo ago −0.15%α −0.22% · $204.67
- T+5 · 7mo ago −0.11%α −4.24% · $204.77
- T+20 · 7mo ago +1.55%α −7.44% · $208.16
- T+60 · 5mo ago +22.47%α +9.01% · $251.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbbVie updated its 2026 adjusted diluted EPS guidance to $13.96–$14.16, incorporating a $0.41 per share impact from Q1 2026 acquired IPR&D and milestones expense. This follows the company's prior full-year guidance of $14.37–$14.57, which excluded such expenses.
Key Facts
- AbbVie issued updated 2026 full-year adjusted diluted EPS guidance of $13.96–$14.16, down from prior range of $14.37–$14.57
- The reduction reflects a $0.41 per share impact from acquired IPR&D and milestones expense incurred in Q1 2026
- The company does not forecast future IPR&D or milestones expenses due to uncertainty in timing and occurrence
- This filing provides preliminary estimates; final results are subject to closing procedures
Financial Impact
Full-year adjusted EPS guidance reduced by $0.41 to $13.96–$14.16, reflecting $744 million in Q1 2026 acquired IPR&D and milestones expense
Risk Factors
- Future IPR&D and milestones expenses remain uncertain and could further impact earnings
- Preliminary estimates are subject to change upon final financial closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000011 |
| Document: abbv-20260331nonxgaapxex991.htm | 0001551152-26-000011 |
| Document: 0001551152-26-000011-index-headers.html | 0001551152-26-000011 |
| Document: 0001551152-26-000011-index.html | 0001551152-26-000011 |
| Document: 0001551152-26-000011.txt | 0001551152-26-000011 |
| 8-K Data (Synthetic) | 0001551152-26-000011 |
Track record
22 reports on ABBV
7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers